Tuesday, November 18, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft ...

Mazur, GM of LillyDirect, breaks down the platform’s new partnership with Walmart and its implications for the pharma ...

The new generation of obesity medications are inducing greater weight loss than any prior pharmacotherapy. There is discussion now about how to support fat loss while protecting lean mass.“Lean mass ...

Researchers reported that Eli Lilly’s GLP-1 weight-loss drug appeared to temporarily suppress food-craving signals in the ...

Novo Nordisk announced Monday that it is significantly cutting the prices of its blockbuster GLP-1 drugs, Wegovy (for weight ...

A GLP-1/glucagon dual agonist induced significant weight loss and improved multiple cardiometabolic parameters for adults ...

Eli Lilly shares have room to keep going as GLP-1 drugs spread their reach.

The introduction of AbbVie’s hepatitis C drugs in 2014 forced Gilead’s hand in the fight for market dominance in hepatitis C.

Pfizer's CEO certainly thinks so. In a TV interview, Bourla said: "Pfizer, when it plays, plays big. And we will -- as we did in COVID, as we did with Lipitor, as we did with ... Viagra, as we did ...

Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without ...

Even $149 a month, the advertised price for a starting dose of a still-in-development GLP-1 pill on TrumpRx, will be too big ...

The drugmaker said Monday that it has started selling higher doses of the injectable obesity treatment for $349 a month to ...